An Overview of Types, Diagnosis, and Treatment

Cancer involves abnormal cells growing uncontrollably, invading nearby tissues, and spreading to other parts of the body through metastasis. 

We're Here to Help.
Get in Touch.

Send us all your questions or requests, and our expert team will assist you.

Doctors
GDPR

Surgical Management: Wide Local Excision

Surgical Management: Wide Local Excision

Surgery is the primary treatment for early-stage melanoma and is curative for the majority of patients. The standard procedure is a Wide Local Excision (WLE). After the diagnostic biopsy confirms melanoma, the surgeon must go back and remove a safety margin of normal-appearing skin around the original tumor site. This ensures that any microscopic cancer cells spreading horizontally in the skin are removed.

The Breslow depth of the tumor strictly dictates the width of this margin:

  • Melanoma in situ (non-invasive): 0.5 cm to 1 cm margin.
  • Thin melanoma (<1 mm): 1 cm margin.
  • Intermediate thickness (1-2 mm): 1 cm to 2 cm margin.
  • Thick melanoma (>2 mm): 2 cm margin.

The excision extends down to the muscle fascia (the covering of the muscle) to ensure the full depth of the skin and subcutaneous fat is cleared. The wound is then closed with sutures. In some cases, particularly on the face or lower legs, where skin is tight, a skin graft or a flap (moving skin from a nearby area) may be required to close the wound.

  • WLE removes a safety margin of healthy tissue.
  • Margin width is determined by tumor thickness.
  • Deep margins extend to the muscular fascia.
  • Reconstruction may require grafts or flaps.
  • Surgery alone cures most localized melanomas.
Icon LIV Hospital

Management of Regional Lymph Nodes

Management of Regional Lymph Nodes

If the Sentinel Lymph Node Biopsy is positive, it indicates that the cancer has spread to the regional basin. Historically, patients with a positive sentinel node underwent a Completion Lymph Node Dissection (CLND), in which all remaining lymph nodes in the area (axilla, groin, or neck) were surgically removed.

However, recent major clinical trials (like MSLT-II) have shifted this paradigm. Data showed that for many patients with a small amount of cancer in the sentinel node, removing all the remaining nodes did not improve overall survival compared to monitoring them closely with ultrasound. Therefore, CLND is now performed less frequently. It is generally reserved for patients with bulky nodal disease (nodes that can be felt) or enormous burdens of metastatic disease in the sentinel node.

Instead of immediate extensive surgery, patients with positive sentinel nodes are typically offered Adjuvant Systemic Therapy (immunotherapy or targeted therapy). This treats the whole body, targeting residual cells in remaining nodes and distant organs, providing a survival benefit without the morbidity of complete nodal dissection (such as lymphedema).

  • Completion dissection is no longer automatic for positive sentinel nodes.
  • Ultrasound surveillance is a safe alternative for microscopic nodal disease.
  • Extensive dissection is reserved for bulky, palpable nodal disease.
  • The focus has shifted to adjuvant systemic therapy for nodal involvement.
  • This approach reduces surgical morbidity like lymphedema.
Icon 1 LIV Hospital

Immunotherapy: Checkpoint Inhibitors

Immunotherapy: Checkpoint Inhibitors

The treatment of advanced melanoma has been revolutionized by immunotherapy, particularly checkpoint inhibitors. These drugs do not kill cancer cells directly; instead, they unleash the patient’s own immune system to fight the tumor.

PD-1 Inhibitors (Pembrolizumab, Nivolumab) target the PD-1 receptor on T-cells. Typically, cancer cells bind to PD-1 to tell the T-cell, “don’t attack me.” By blocking this interaction, these drugs remove the “brakes” on the immune system, allowing T cells to recognize and destroy the melanoma.

CTLA-4 Inhibitors (Ipilimumab) work at an earlier stage of immune activation. CTLA-4 is a protein that downregulates the immune system. Blocking it enhances the priming and expansion of T-cells in the lymph nodes.

These drugs can be used alone (monotherapy) or in combination. The combination of Ipilimumab and Nivolumab is highly potent and has significantly extended survival for Stage IV patients, though it carries a higher risk of immune-related side effects. Immunotherapy is used both for unresectable metastatic disease and as adjuvant therapy after surgery for Stage III/IV patients to prevent recurrence.

  • Checkpoint inhibitors remove immune suppression signals.
  • PD-1 inhibitors reactivate T-cells within the tumor microenvironment.
  • CTLA-4 inhibitors enhance T-cell priming in lymph nodes.
  • Combination therapy offers higher response rates but increased toxicity.
  • Immunotherapy induces durable, long-term responses in many patients.

Targeted Therapy: BRAF and MEK Inhibitors

Targeted Therapy: BRAF and MEK Inhibitors

Approximately 50% of cutaneous melanomas harbor a BRAF mutation (specifically V600E or V600K). This mutation turns the BRAF protein into a constantly active switch that drives cell division via the MAPK pathway. Targeted Therapy exploits this specific genetic vulnerability.

Patients with advanced melanoma are routinely tested for BRAF mutations. If positive, they can be treated with a combination of a BRAF Inhibitor (e.g., Dabrafenib, Vemurafenib, Encorafenib) and a MEK Inhibitor (e.g., Trametinib, Cobimetinib, Binimetinib). MEK is a protein downstream of BRAF; blocking both points in the pathway shuts down the growth signal more effectively and delays the development of drug resistance.

Unlike immunotherapy, which can take time to work, targeted therapy often produces rapid tumor shrinkage, making it excellent for patients with a high symptom burden. However, tumors can eventually develop resistance to these drugs. Therefore, they are often sequenced with immunotherapy. It is important to note that targeted therapy is ineffective in BRAF-wildtype (negative) patients.

  • Targeted therapy requires a BRAF mutation.
  • BRAF and MEK inhibitors block the hyperactive MAPK signaling pathway.
  • Dual inhibition prevents resistance and improves outcomes.
  • Rapid tumor response is a hallmark of this modality.
  • It serves as a critical option for patients with mutations.

Radiation and Regional Therapies

While melanoma was historically considered radio-resistant, Radiation Therapy plays a specific role. It is rarely used as a primary cure. Still, it is valuable as Adjuvant Radiation after lymph node dissection if there is a high risk of local recurrence (e.g., many positive nodes or extracapsular extension). It is also widely used for Palliation, shrinking tumors that are causing pain, bleeding, or pressing on vital structures like the spinal cord or brain. Stereotactic Radiosurgery (Gamma Knife) is highly effective for treating melanoma brain metastases.

For melanoma confined to a limb (e.g., multiple nodules on a leg) that cannot be surgically removed, Isolated Limb Perfusion (ILP) or Infusion (ILI) may be used. These procedures involve surgically isolating the blood flow of the affected limb and circulating high-dose chemotherapy (Melphalan) and heat only through that leg. This delivers a potent dose to the tumor without exposing the rest of the body to toxic side effects.

Talimogene laherparepvec (T-VEC) is an oncolytic virus therapy injected directly into melanoma nodules. It is a modified herpes virus that infects cancer cells, causing them to burst, and simultaneously stimulates the immune system to attack nearby tumor cells.

  • Radiation serves as an adjuvant and a palliative role.
  • Stereotactic radiosurgery is effective for brain metastases.
  • Isolated limb therapies deliver regional high-dose chemotherapy.
  • ILP/ILI spares the systemic circulation from toxicity.
  • Oncolytic viral therapy (T-VEC) provides local tumor lysis and immune stimulation.

Book a Free Certified Online
Doctor Consultation

Clinics/branches
GDPR

Related Doctors

Assoc. Prof. MD. Evrim Duman Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology Asst. Prof. MD. Meltem Topalgökçeli Selam Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology Prof. MD. Duygu Derin Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology Prof. MD. Emre Merdan Fayda Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology Prof. MD. Meral Günaldı Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology Assoc. Prof. MD. Murat Ayhan Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology Prof. MD.  Itır Şirinoğlu Demiriz Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology Prof. MD. Tülin Tıraje Celkan Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology Assoc. Prof. MD. Erkan Kayıkçıoğlu Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology Assoc. Prof. MD. Mine Dağgez Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology Assoc. Prof. MD. Ozan Balakan Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology MD. Taylan Bükülmez Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology Op. MD. Alp Koray Kinter Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology Prof. MD. Nuri Faruk Aykan Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology Spec. MD. Özlem Doğan Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology Assoc. Prof. MD. Emir Çelik Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology Assoc. Prof. MD. Muhammed Mustafa Atcı Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology Prof. MD. İrfan Çiçin Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology Assoc. Prof. MD.  Ramazan Öcal Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology Assoc. Prof. MD. Nazlı Topfedaisi Özkan Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology Prof. MD. Fikret Arpacı Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology Prof. MD. Gökhan Erdem Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology Prof. MD. Meral Beksaç Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology Prof. MD. Oral Nevruz Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology Prof. MD. Saadettin Kılıçkap Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology Prof. MD. Sadık Muallaoğlu Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology Spec. MD. Ender Kalacı Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology Assoc. Prof. MD. Fadime Ersoy Dursun Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology Prof. MD. Fatih Teker Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology Spec. MD. ELXAN MEMMEDOV Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology Spec. MD. Ceyda Aslan Spec. MD. Ceyda Aslan Hematology Spec. MD. Elkhan Mammadov Spec. MD. Elkhan Mammadov Medical Oncology Spec. MD. Elmir İsrafilov Spec. MD. Elmir İsrafilov Hematology Spec. MD. Minure Abışova Eliyeva Spec. MD. Minure Abışova Eliyeva Hematology Spec. MD. Natavan Azizova Spec. MD. Natavan Azizova Medical Oncology Prof. MD. Mehmet Hilmi Doğu Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology

30 Years of
Excellence

Trusted Worldwide

With patients from across the globe, we bring over three decades of medical

Group 346 LIV Hospital

Reviews from 9,651

4,9

Was this article helpful?

Was this article helpful?

We're Here to Help.
Get in Touch.

Send us all your questions or requests, and our expert team will assist you.

Doctors
GDPR

FREQUENTLY ASKED QUESTIONS

What is the difference between adjuvant and neoadjuvant therapy?

Adjuvant therapy is given after the primary surgery to clean up any microscopic cells left behind and lower the risk of the cancer coming back. Neoadjuvant treatment is given before surgery to shrink the tumor, making it easier to remove, and to test how well the cancer responds to the drug while it is still visible.

For Stage III or IV patients where the cancer has been surgically removed (adjuvant setting), the standard treatment duration is usually one year. For patients with metastatic disease that cannot be removed, treatment usually continues for as long as it is working and side effects are manageable, often up to two years or more.

Targeted therapy drugs work like a key that fits a specific lock. The “lock” is the mutated BRAF protein. If your cancer does not have the BRAF mutation (BRAF wild-type), it doesn’t have that specific lock. Taking the drug would be ineffective because there is nothing for it to target, and it could actually cause harm by activating normal cells.

No, the actual delivery of radiation is painless, like getting an X-ray. You cannot feel the beam. However, side effects can develop over time, such as skin redness (like a sunburn) in the treated area, fatigue, or hair loss at the specific site.

A complete response means that all detectable signs of cancer have disappeared on scans and exams. While this is the goal, even patients with a “partial response” (tumor shrinks but doesn’t vanish) or “stable disease” (tumor stops growing) can live for many years with a good quality of life on these treatments.

Spine Hospital of Louisiana
Need Help? Chat with our medical team

Let's Talk on WhatsApp

📌

Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.

or call us at +90 530 174 26 75

How helpful was it?

helpful
GDPR
helpful
GDPR
helpful
GDPR